KU Medical Center Continuing Education

The conference is full. Registration is now closed. Walk-ins will not be accepted for this event. Thank you for your interest.

Sponsored by the Division of Hematology/Oncology and University of Kansas Medical Center Continuing Education

The goal of this symposium is to disseminate key practice-changing information presented during the 2012 Annual Meeting of the Gastrointestinal Cancers Symposium. In order to promote current professional education and facilitate the delivery of high-quality care to cancer patients, discussion will focus on relevant data regarding the integration of new cancer management strategies into clinical practice. Cancer types to be addressed include: colorectal; esophageal; stomach; pancreatic; hepatobiliary; neuroendocrine; and gastrointestinal stromal tumors. Advances in translational medicine and novel agents in clinical development will also be reviewed. Late-breaking data will be made reachable to practicing cancer-care providers. Through didactic and question-and-answer sessions, faculty will communicate to cancer-care providers the most current information pertaining to their specializations.

Target Audience

This educational program is designed for:

• medical oncologists
• radiation oncologists
• surgical oncologists
• colorectal surgeons
• gastroenterologists
• pathologists
• radiologists
• internal medicine and primary care physicians
• basic scientists
• nurses
• pharmacists
• other medical professionals involved in the care and research investigations of patients with gastrointestinal malignancies

Objectives

At the completion of this symposium, participants should be able to:

• identify newly recognized promising agents that target novel molecular pathways (including new anti-VEGF and VEGFR, IGFR, c-Met, mTOR, and PI3KCa inhibitors; angiopoietin; death pathway agonists; and newer multi-targeted agents for treating patients with colorectal cancer; and esophageal, gastric, pancreatic, hepatobiliary, small bowel, neuroendocrine, and gastrointestinal stromal tumors.
• compare and contrast innovative approaches and the latest tools available in the selection of patients appropriate for adjuvant therapy in colorectal cancer.
• identify the multimodality approach in the treatment of patients with colorectal cancers.
• personalize patient care by evaluating new information regarding the use of chemotherapy and targeted agents with molecular guidance in the treatment of colorectal cancer.
• recognize new molecular markers with prognostic and predictive importance in esophageal and gastric cancer.
• examine these molecular markers in designing therapeutic strategies in esophageal and gastric cancers.
• debate the pros and cons of neoadjuvant and adjuvant therapy for pancreatic cancer patients.
• evaluate the latest results of clinical trials regarding the use of systemic (chemotherapy and targeted agents) and loco-regional therapy for liver, biliary-tract and pancreatic malignancies.
• debate the latest diagnostic and therapeutic advances in the treatment of gastrointestinal stromal tumors.

Acknowledgments

Financial contributions and supporters of this program will be acknowledged in print at the symposium.

Exhibits

Commercial vendors are invited to exhibit at this meeting. Limited exhibit space will be available. Call Julie Darrington at 913-588-4581 or e-mail jdarrington@kumc.edu for an application or more information.